DC-PGKI

Overview

DC-PGKI is an orally active ATP-competitive PGK1 inhibitor( IC 50 = 0.16 Μm, K d = 99.08 nM). DC-PGKI stabilizes PGK1 in vitro and in vivo, and suppresses both glycolytic activity and the kinase function of PGK1. DC-PGKI-mediated inhibition of PGK1 leads to the accumulation of NRF2 (nuclear factor-erythroid factor 2-related factor 2, NFE2L2), which then translocates to the nucleus, binds to the proximal regions of IL-1β and IL-6 genes, and suppresses the LPS-induced expression of these genes. DC-PGKI can be used for the study of colitis.

Application

Products | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Phosphoglycerate Kinase (PGK) | Products > Signaling Pathways > Keap1-Nrf2 | Products > Signaling Pathways > Interleukin Related

Product Information

• Catalog No.: HY-177944
• CAS No.: 2829198-49-2
• Molecular Formula: C26H29Cl2N7O3
• Molecular Weight: 558.46
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source